• Measure Summary
  • NQMC:011141
  • 2015 Mar

Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing disease specific treatment (liver transplant, resection, ablation, trans-arterial chemoembolisation [TACE] or systemic anti-cancer therapy [SACT]) who die within 30 days of definitive treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011041
  • 2016 Jan

Ovarian cancer: proportion of patients with early stage epithelial ovarian cancer (FIGO stage 1) undergoing primary surgery who have an adequate staging operation involving total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), omentectomy and washings.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011270
  • 2016 Feb

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing wide local excision within 84 days of their diagnostic excision biopsy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011069
  • 2016 Jun

Bladder cancer: proportion of patients with muscle invasive bladder cancer (MIBC) who are discussed at the multidisciplinary team (MDT) meeting before definitive treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011038
  • 2016 Jan

Ovarian cancer: proportion of patients with stage 1 epithelial ovarian cancer having Risk of Malignancy Index (RMI) assessed and recorded in their notes prior to any definitive surgical intervention.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011231
  • 2017 Feb

Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) who receive curative treatment (radical radiotherapy, radical chemoradiotherapy or surgical resection) who undergo PET CT prior to start of treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011105
  • 2016 Oct

Renal cancer: proportion of patients with T1aN0M0 renal cell carcinoma (RCC) who undergo nephron sparing surgery (NSS) (laparoscopic partial nephrectomy or open partial nephrectomy).

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011158
  • 2016 Jun

Testicular cancer: proportion of patients with stage I testicular non-seminomatous (or mixed) germ cell tumour (NSGCT) who undergo at least three CT scans of the abdomen +/- chest and pelvis within 14 months of diagnosis.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011175
  • 2016 Aug

Cervical cancer: proportion of patients with cervical cancer who have an MRI of the pelvis performed prior to definitive treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011118
  • 2016 May

Sarcoma: proportion of patients with extremity sarcoma who undergo a primary limb-sparing surgery.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011138
  • 2015 Mar

Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing either CT or MRI and with full information recorded.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011124
  • 2016 May

Sarcoma: proportion of patients with sarcoma who undergo surgical resection or oncological treatment with curative intent who die within 30 days of treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011171
  • 2015 Jan

Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who receive curative oncological treatment who die within 30 days of treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011234
  • 2017 Feb

Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) undergoing resection by lobectomy or pneumonectomy who have at least 1 node from at least 3 N2 stations sampled at time of resection or at previous mediastinoscopy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011188
  • 2015 Sep

Lymphoma: proportion of patients with lymphoma who are discussed at a multidisciplinary team (MDT) meeting within 6 weeks of diagnosis.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011075
  • 2016 Jun

Bladder cancer: proportion of patients with high risk non muscle invasive bladder cancer (NMIBC) who have undergone transurethral resection of bladder tumour (TURBT) who have a second TURBT or early cystoscopy (± biopsy) within 6 weeks (42 days) of initial resection.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011199
  • 2016 Jul

Prostate cancer: proportion of patients with non-metastatic prostate cancer (TanyNanyM0) discussed at the multidisciplinary team (MDT) meeting before definitive treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011178
  • 2016 Aug

Cervical cancer: proportion of patients with FIGO stage IB1 cervical cancer who undergo radical hysterectomy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011093
  • 2016 Jan

Brain and central nervous system (CNS) cancer: proportion of patients with resectable malignant glioma (with enhancing component on pre-operative imaging) undergoing surgery (biopsy and surgical resection) where greater than 90% reduction in tumour volume is achieved.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011163
  • 2015 Jan

Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who have tumour node metastases (TNM) stage and treatment intent recorded at a multidisciplinary team (MDT) meeting prior to treatment.

NHS Scotland; Scottish Cancer Taskforce